FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016279298> ?p ?o ?g. }

• W2016279298 endingPage "993" @default.
• W2016279298 startingPage "992" @default.
• W2016279298 abstract "We read with interest the retrospective study on renal tubular dysfunction (RTD) during nucleotide analogue (NA) therapy in chronic hepatitis B (CHB).1 RTD was diagnosed by a new definition, but all seven patients developed previously evaluated renal dysfunction markers, such as creatinine clearance (CrCl) <60 mL/min (<50 in five cases) and hypohosphataemia ≤2.3 mg/dL (≤2.0 in four cases). The authors concluded that RTD develops in 15% of CHB patients treated with adefovir/tenofovir for 2–9 years, which is questionable, at least for tenofovir, for several reasons. First, most patients (47/51) started with adefovir, while only 4 started with tenofovir and 5 additional cases switched from adefovir to tenofovir. Similar probabilities of CrCl decrease have been reported for adefovir,2, 3 whereas large 5-year phase III (n = 490) and 2.5-year real-life cohort (n = 302) studies have reported minimal (<2%) rates of CrCl <50 mL/min and/or hypophosphataemia <2 mg/dL in tenofovir-treated naive CHB patients.4, 5 Given the small number of tenofovir-treated patients in the study, the confidence intervals for RTD rates are impressively wide (0–49%). Second, the small total patient number (possible type II error) might have hidden an influence of comorbidities reported in 57% and 39% of patients with and without RTD. Third, the authors did not report any adefovir/tenofovir dose modification in case of RTD signs and therefore cannot comment on the outcome of such a strategy. Finally, the probability of clinical bone effects from hypophosphataemia remains unclear, as mild alkaline phosphatase increases were reported in three patients and no bone biopsy was performed. In conclusion, we agree that appropriate renal monitoring is required for all CHB patients treated with NAs, as suggested by recent guidelines,6 but we believe that there is still no clear evidence on the probability of tenofovir nephrotoxicity in CHB. Results from large and well-designed long-term studies are awaited. Declaration of personal interests: Spilios Manolakopoulos has served as a speaker, a consultant and an advisory board member for Bristol-Myers Squibb, Gilead, Merck, Novartis and Roche, and has received research funding from Bristol-Myers Squibb and Roche. Athanasia Striki has nothing to disclose. George Papatheodoridis has served as a speaker, a consultant and an advisory board member for Bristol-Myers Squibb, Gilead, Merck, Novartis and Roche, and has received research funding from Bristol-Myers Squibb, Gilead and Roche. None of the authors is an employee of any pharmaceutical company, owns stocks and shares in any pharmaceutical company or owns any patent. Declaration of funding interests: None." @default.
• W2016279298 created "2016-06-24" @default.
• W2016279298 creator A5016318276 @default.
• W2016279298 creator A5030128305 @default.
• W2016279298 creator A5090574022 @default.
• W2016279298 date "2012-10-17" @default.
• W2016279298 modified "2023-10-18" @default.
• W2016279298 title "Letter: renal tubular dysfunction during nucleotide analogue therapy in chronic hepatitis B" @default.
• W2016279298 cites W1967427303 @default.
• W2016279298 cites W1986864408 @default.
• W2016279298 cites W1987753756 @default.
• W2016279298 cites W2236833848 @default.
• W2016279298 cites W4211026375 @default.
• W2016279298 doi "https://doi.org/10.1111/apt.12065" @default.
• W2016279298 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23072605" @default.
• W2016279298 hasPublicationYear "2012" @default.
• W2016279298 type Work @default.
• W2016279298 sameAs 2016279298 @default.
• W2016279298 citedByCount "2" @default.
• W2016279298 countsByYear W20162792982012 @default.
• W2016279298 countsByYear W20162792982013 @default.
• W2016279298 crossrefType "journal-article" @default.
• W2016279298 hasAuthorship W2016279298A5016318276 @default.
• W2016279298 hasAuthorship W2016279298A5030128305 @default.
• W2016279298 hasAuthorship W2016279298A5090574022 @default.
• W2016279298 hasConcept C126322002 @default.
• W2016279298 hasConcept C126894567 @default.
• W2016279298 hasConcept C159047783 @default.
• W2016279298 hasConcept C159641895 @default.
• W2016279298 hasConcept C167135981 @default.
• W2016279298 hasConcept C2522874641 @default.
• W2016279298 hasConcept C2777382497 @default.
• W2016279298 hasConcept C2777869810 @default.
• W2016279298 hasConcept C2779344132 @default.
• W2016279298 hasConcept C2779517838 @default.
• W2016279298 hasConcept C2780091579 @default.
• W2016279298 hasConcept C2780306776 @default.
• W2016279298 hasConcept C3013748606 @default.
• W2016279298 hasConcept C3020491458 @default.
• W2016279298 hasConcept C71924100 @default.
• W2016279298 hasConcept C72563966 @default.
• W2016279298 hasConcept C90924648 @default.
• W2016279298 hasConceptScore W2016279298C126322002 @default.
• W2016279298 hasConceptScore W2016279298C126894567 @default.
• W2016279298 hasConceptScore W2016279298C159047783 @default.
• W2016279298 hasConceptScore W2016279298C159641895 @default.
• W2016279298 hasConceptScore W2016279298C167135981 @default.
• W2016279298 hasConceptScore W2016279298C2522874641 @default.
• W2016279298 hasConceptScore W2016279298C2777382497 @default.
• W2016279298 hasConceptScore W2016279298C2777869810 @default.
• W2016279298 hasConceptScore W2016279298C2779344132 @default.
• W2016279298 hasConceptScore W2016279298C2779517838 @default.
• W2016279298 hasConceptScore W2016279298C2780091579 @default.
• W2016279298 hasConceptScore W2016279298C2780306776 @default.
• W2016279298 hasConceptScore W2016279298C3013748606 @default.
• W2016279298 hasConceptScore W2016279298C3020491458 @default.
• W2016279298 hasConceptScore W2016279298C71924100 @default.
• W2016279298 hasConceptScore W2016279298C72563966 @default.
• W2016279298 hasConceptScore W2016279298C90924648 @default.
• W2016279298 hasIssue "10" @default.
• W2016279298 hasLocation W20162792981 @default.
• W2016279298 hasLocation W20162792982 @default.
• W2016279298 hasOpenAccess W2016279298 @default.
• W2016279298 hasPrimaryLocation W20162792981 @default.
• W2016279298 hasRelatedWork W1967495748 @default.
• W2016279298 hasRelatedWork W1977555849 @default.
• W2016279298 hasRelatedWork W2026231483 @default.
• W2016279298 hasRelatedWork W2115814773 @default.
• W2016279298 hasRelatedWork W2238322577 @default.
• W2016279298 hasRelatedWork W2340964019 @default.
• W2016279298 hasRelatedWork W2377006731 @default.
• W2016279298 hasRelatedWork W2413530128 @default.
• W2016279298 hasRelatedWork W3031966738 @default.
• W2016279298 hasRelatedWork W3117361317 @default.
• W2016279298 hasVolume "36" @default.
• W2016279298 isParatext "false" @default.
• W2016279298 isRetracted "false" @default.
• W2016279298 magId "2016279298" @default.
• W2016279298 workType "letter" @default.